IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Joseph S. Podolski	Title:	METHODS AND COMPOSITIONS	
App. No.:	10/712,546		WITH TRANS-CLOMIPHENE FOR TREATING WASTING AND	
Conf. No.:	9175		LIPODYSTROPHY	

Filing Date: November 12, 2003 Art Unit: 1614

Docket No: 07189.0028.CPUS02 Examiner: Kwon, Brian Yong S.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the reference listed on the attached Form PTO/SB/08B. It is respectfully requested that this Information Disclosure Statement be entered and the document listed on attached Forms PTO/SB/08B be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g), this Information Disclosure Statement is not to be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), this Information Disclosure Statement is not to be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise Application No. 10/712,546 Filed: November 12, 2003 Page 2

closes prosecution in this application. The Commissioner is hereby authorized to deduct the fee of \$180.00 set forth in §1.17(p) from Howrey LLP Deposit Account 08-3038 referencing the above-identified attorney docket number, and hence this Information Disclosure Statement is believed to be timely filed in accordance with 37 C.F.R. §1.97(c)(2). No other fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any additional fees under 37 C.F.R. §§1.16 to 1.21 be deemed necessary for any reasons relating to this document, the Commissioner is hereby authorized to deduct the fees from the above-identified Deposit Account.

Respectfully submitted,

HOWREYLLP

Dated: August 25, 2006

By: David W. Clough, Ph.D. Registration No.: 36,107 Customer No.: 22930

HOWREY LLP 321 N. Clark Street, Suite 3400 Chicago, IL 60661 (312) 595-1239 (main) (312) 595-1408 (direct) (312) 595-2250 (fax) Approved for use through 05/30/2005 OMB 0651-0031 ection of information unless if contains a valid OMR control number

Substitute for form 1449B/PTO		Complete if Known		
		Application Number	10/712,546	
INFORMATIO	ON DISCLOSURE	Filing Date	November 12, 2003	
STATEMENT	BY APPLICANT	First Named Inventor	Joseph S. Podolski	
		Art Unit	1614	
(Usa as many	sheets as necessary)	Examiner Namo	Kwon, Brian Yong S.	
Sheet 1	of 1	Altorney Docket Number	07189.0028.CPUS02	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C29	Chang, C-F, et at., "Stimulation of Ovulation in Ayu, Plecoglossus-Altivelis, by Treatment with Antiestrogens and Luteinizing Hormone-Releasing Hormone Analog," Aquaculture, Vol. 101. Nos. 34, pp. 329-336 (1992)	

Examiner Signature	Date Considered	

**COLUMNET, Intel of subjects or contraction, set that or cot detains a in confirmance with MEPF-040. Dear the sample profit for a first incommon each for contraction to oppose, and opposed profit or contraction to oppose and opposed profit or contraction to oppose a contraction of the contraction

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.